FGL2 and cancer: FGL2 expression has been associated with poor survival in a number of different cancers such as glioblastoma multiforme28,30,31, colorectal32, renal33, liver25,34,35, and prostate cancer36 primarily through its prothrombinase function, as well as a mediator of immunosuppression.